Ninlaro and Swallowing difficulty - a phase IV clinical study of FDA data

Summary:

Swallowing difficulty is reported as a side effect among people who take Ninlaro (ixazomib citrate), especially for people who are male, 60+ old, have been taking the drug for < 1 month also take Revlimid, and have Multiple myeloma.

The phase IV clinical study analyzes which people have Swallowing difficulty when taking Ninlaro. It is created by eHealthMe based on reports of 19,558 people who have side effects when taking Ninlaro from the FDA, and is updated regularly.

What is Ninlaro?

Ninlaro has active ingredients of ixazomib citrate. eHealthMe is studying from 19,563 Ninlaro users. Check the latest studies of Ninlaro.

What is Swallowing difficulty?

Swallowing difficulty is found to be associated with 2,403 drugs and 3,350 conditions by eHealthMe. Check the latest studies of Swallowing difficulty.

On Jul, 06, 2026

19,558 people reported to have side effects when taking Ninlaro.
Among them, 36 people (0.18%) have Swallowing difficulty.

Could Ninlaro cause Swallowing difficulty?

Among these 36 people:

How long have people been on Ninlaro when they have Swallowing difficulty? *

What is the gender of people who have Swallowing difficulty when taking Ninlaro? *

female: 40 %
male: 60 %

What is the age of people who have Swallowing difficulty when taking Ninlaro? *

What are other drugs people take besides Ninlaro? *

What are other side effects people have besides Swallowing difficulty? *

Diarrhea: 9 people, 25.00%
Back Pain: 8 people, 22.22%
Dehydration (dryness resulting from the removal of water): 7 people, 19.44%
Dizziness: 6 people, 16.67%
Weight Decreased: 6 people, 16.67%
Appetite - Decreased (decreased appetite occurs when you have a reduced desire to eat): 5 people, 13.89%
Headache (pain in head): 5 people, 13.89%
Urinary Tract Infection: 5 people, 13.89%
Nausea (feeling of having an urge to vomit): 5 people, 13.89%
Fatigue (feeling of tiredness): 5 people, 13.89%

What are the existing conditions these people have? *

Multiple Myeloma (cancer of the plasma cells): 30 people, 83.33%
Progressive Multifocal Leukoencephalopathy (rapidly progressive neuromuscular disease caused by opportunistic infection of brain cells): 3 people, 8.33%
Pain: 2 people, 5.56%
Neoplasm Malignant (cancer tumour): 2 people, 5.56%
Nausea (feeling of having an urge to vomit): 2 people, 5.56%
Haemorrhage (bleeding): 2 people, 5.56%
Fever: 2 people, 5.56%
Acute Myeloid Leukaemia (acute cancer in which the bone marrow makes abnormal myeloblasts): 1 person, 2.78%

* Approximation only. Some reports may have incomplete information.

Do you take Ninlaro and have Swallowing difficulty?

- Check whether Swallowing difficulty is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Ninlaro:

Ninlaro (19,563 reports)

Browse all side effects of Ninlaro:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Swallowing difficulty:

Swallowing difficulty (2,403 drugs)

Browse all the conditions that are associated with Swallowing difficulty:

Swallowing difficulty (3,350 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on ixazomib citrate (the active ingredients of Ninlaro) and Ninlaro (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.